Abstract: Objectives: Investigate possible predictors of response to IV lidocaine, defined as greater than 30% reduction in NRS. The secondary aim was to quantify the efficacy of lidocaine infusion in terms of duration of meaningful decrease in pain in patients with neuropathic pain. Recognize the safety profile by documenting the incidence of various side effects. Material and Methods: We conducted a retrospective cohort study of patients 335 patients that received 617 infusions Results: Age, baseline pain severity, degree of pain relief provided by first infusion, presence of psychiatric diagnosis and insomnia are clinical predictors of response to IV Lidocaine therapy. Lidocaine provides, clinically significant but short term pain relief. Discussion: Current literature supports our findings that duration of pain and refractoriness to other pain medication doesn’t predict the response. There is no study that has commented on the association of psychiatric disorders and insomnia with clinical response to Lidocaine. The safety profile of Lidocaine is excellent with a few minor side effects like light-headedness, dizziness, perioral numbness being most common. These findings are consistent with the findings of Hutson et al.